These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35625960)

  • 1. Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma.
    Jee B; Seo E; Park K; Kim YR; Byeon SJ; Lee SM; Chung JH; Song W; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park SH; Park WY; Kang M
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
    Hagiwara M; Fushimi A; Matsumoto K; Oya M
    Eur Urol; 2022 Feb; 81(2):145-148. PubMed ID: 34627641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.
    Miao D; Margolis CA; Gao W; Voss MH; Li W; Martini DJ; Norton C; Bossé D; Wankowicz SM; Cullen D; Horak C; Wind-Rotolo M; Tracy A; Giannakis M; Hodi FS; Drake CG; Ball MW; Allaf ME; Snyder A; Hellmann MD; Ho T; Motzer RJ; Signoretti S; Kaelin WG; Choueiri TK; Van Allen EM
    Science; 2018 Feb; 359(6377):801-806. PubMed ID: 29301960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade.
    Yoshida T; Ohe C; Ikeda J; Atsumi N; Ohsugi H; Sugi M; Higasa K; Saito R; Tsuta K; Matsuda T; Kinoshita H
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34580162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma.
    Aili A; Wen J; Xue L; Wang J
    Front Oncol; 2021; 11():712765. PubMed ID: 34447697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma.
    Xu Z; Jiang W; Liu L; Qiu Y; Wang J; Dai S; Guo J; Xu J
    Cancer Immunol Immunother; 2024 Apr; 73(5):95. PubMed ID: 38607586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
    Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of PD-L1 expression in PBRM1-altered clear cell renal cell carcinoma.
    Lee J; Moon S; Kwon HJ; Lee S; Choe G; Lee KS
    Urol Oncol; 2024 Dec; 42(12):454.e21-454.e30. PubMed ID: 39341712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
    Eckel-Passow JE; Serie DJ; Cheville JC; Ho TH; Kapur P; Brugarolas J; Thompson RH; Leibovich BC; Kwon ED; Joseph RW; Parker AS
    BMC Urol; 2017 Mar; 17(1):19. PubMed ID: 28327121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of PBRM1 mutation in disease progress and drug selection in clear cell renal cell carcinoma.
    He D; Ma T; Yi N; Zhang S; Ding G
    Biotechnol Genet Eng Rev; 2024 Dec; 40(4):3901-3915. PubMed ID: 37079762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers.
    Dai J; Cui Y; Liang X; Xu J; Li J; Chen Y; Zhang E; Guo R
    Front Genet; 2022; 13():1066347. PubMed ID: 36699446
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise chemotherapy and immunotherapy.
    Meng J; Jiang A; Lu X; Gu D; Ge Q; Bai S; Zhou Y; Zhou J; Hao Z; Yan F; Wang L; Wang H; Du J; Liang C
    Imeta; 2023 Nov; 2(4):e147. PubMed ID: 38868222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a PBRM1-associated immune prognostic model for clear cell renal cell carcinoma.
    Chen J; Yao C; Qiao N; Ge Y; Li J; Lin Y; Yao S
    Cancer Med; 2021 Oct; 10(19):6590-6609. PubMed ID: 34535962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Infiltration of Neutrophil Granulocytes Due to Loss of PTEN Was Associated with Poor Response to Immunotherapy in Renal Cell Carcinoma.
    Wu F; Chen J; Yao K; Fan D; Wang M; Liu Y; Xin S; Sun Z; Li S; Sun Y; Liu Q
    J Inflamm Res; 2022; 15():6553-6567. PubMed ID: 36510494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.
    Meng L; Collier KA; Wang P; Li Z; Monk P; Mortazavi A; Hu Z; Spakowicz D; Zheng L; Yang Y
    Cells; 2023 Dec; 13(1):. PubMed ID: 38201238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
    Brugarolas J
    Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma.
    Ran X; Xiao J; Zhang Y; Teng H; Cheng F; Chen H; Zhang K; Sun Z
    Ther Adv Med Oncol; 2020; 12():1758835920977117. PubMed ID: 33425025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The unique genomic landscape and prognostic mutational signature of Chinese clear cell renal cell carcinoma.
    Xu W; Anwaier A; Liu W; Tian X; Su J; Shi G; Qu Y; Zhang H; Ye D
    J Natl Cancer Cent; 2022 Sep; 2(3):162-170. PubMed ID: 39036450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of PBRM1 in VHL disease-associated clear cell renal cell carcinoma and its putative relationship with the HIF pathway.
    Gad S; Le Teuff G; Nguyen B; Verkarre V; Duchatelle V; Molinie V; Posseme K; Grandon B; Da Costa M; Job B; Meurice G; Droin N; Mejean A; Couve S; Renaud F; Gardie B; Teh BT; Richard S; Ferlicot S
    Oncol Lett; 2021 Dec; 22(6):835. PubMed ID: 34712359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.